Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024.

ABSTRACT:

Background

The cell culture-based inactivated influenza vaccine (ccIIV) was first approved for use in children aged 4-17 years in 2016 in the United States. The approved age indication for ccIIV was expanded to include children 6 months and older beginning the 2022-2023 season. There is limited real-world data on ccIIV effectiveness in children. We assessed ccIIV effectiveness using the test-negative design during the 2023-2024 season.

Methods

Patients aged 6 months to 64 years who sought outpatient or telehealth care for acute respiratory illness were actively recruited between October 2023 and May 2024. Symptom eligibility criteria included cough, with an illness duration of ≤ 7 days. Respiratory samples were tested by reverse transcription polymerase chain reaction to ide

SUBMITTER: Nguyen HQ 

PROVIDER: S-EPMC12392406 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature